Diabetic Macular Edema - Pipeline Review, H1 2014





Published: April 2014

Description


Global Markets Direct’s, ‘Diabetic Macular Edema - Pipeline Review, H1 2014’, provides an overview of the Diabetic Macular Edema’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diabetic Macular Edema and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diabetic Macular Edema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Macular Edema pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
 
 

Reasons to Buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Diabetic Macular Edema Overview 11
Therapeutics Development 12
Pipeline Products for Diabetic Macular Edema - Overview 12
Pipeline Products for Diabetic Macular Edema - Comparative Analysis 13
Diabetic Macular Edema - Therapeutics under Development by Companies 14
Diabetic Macular Edema - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Diabetic Macular Edema - Products under Development by Companies 22
Diabetic Macular Edema - Companies Involved in Therapeutics Development 25
F. Hoffmann-La Roche Ltd. 25
Allergan, Inc. 26
pSivida Corp. 27
GlaxoSmithKline plc 28
Quark Pharmaceuticals, Inc. 29
Santen Pharmaceutical Co., Ltd. 30
Astellas Pharma Inc. 31
Kowa Company, Ltd. 32
Pfizer Inc. 33
Genmab A/S 34
TheraKine Ltd. 35
iCo Therapeutics Inc. 36
NicOx S.A. 37
Regeneron Pharmaceuticals, Inc. 38
Handok Inc. 39
ThromboGenics NV 40
Foamix Ltd. 41
Acucela Inc. 42
Senju Pharmaceutical Co., Ltd. 43
Molecular Design International, Inc. 44
Pfenex Inc. 45
Icon Bioscience, Inc. 46
Eleven Biotherapeutics 47
Ampio Pharmaceuticals, Inc. 48
ActiveSite Pharmaceuticals, Inc. 49
AlphaMab Co., Ltd 50
Diabetic Macular Edema - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Target 52
Assessment by Mechanism of Action 57
Assessment by Route of Administration 62
Assessment by Molecule Type 65
Drug Profiles 68
dexamethasone acetate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
aflibercept - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
fluocinolone acetonide - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
aflibercept - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
DMI-5207 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
betamethasone - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
darapladib - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
iCo-007 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ocriplasmin - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
ripasudil - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
PF-655 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
MP-0112 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
AKB-9778 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
difluprednate - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
PF-04634817 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
49-B - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
dexamethasone dipropionate - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
KH-902 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
ALG-1001 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
fluticasone propionate - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
ranibizumab - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
emixustat hydrochloride - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
teprotumumab - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
nesvacumab - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Drug For Diabetic Macular Edema - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
NCX-434 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
ASP-440 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
NCX-422 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
AVA-101 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
ranibizumab biosimilar - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Plasma Kallikrein Inhibitors Programme - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
EBI-018 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Small Molecule to Inhibit VAP-1 for Diabetic Macular Edema - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
EBI-029 - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Plasma Kallikrein Inhibitors Programme - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
OPK-20018 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
ranibizumab biosimilar - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Protein Therapeutic For Diabetic Macular Edema - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Peptide For Diabetic Macular Edema - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
HL-5511 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
minocycline Gel - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Diabetic Macular Edema - Recent Pipeline Updates 134
Diabetic Macular Edema - Dormant Projects 171
Diabetic Macular Edema - Discontinued Products 173
Diabetic Macular Edema - Product Development Milestones 174
Featured News & Press Releases 174
Apr 14, 2014: pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN 174
Mar 27, 2014: pSivida Announces Resubmission of New Drug Application for ILUVIEN 174
Mar 05, 2014: iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study 174
Mar 03, 2014: Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA Injection for the Treatment of Diabetic Macular Edema in Japan 175
Feb 21, 2014: Novartis shows continued commitment in Japan with Lucentis approval in fourth Japanese indication, diabetic macular edema 176
Feb 13, 2014: Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema 177
Feb 10, 2014: Two-Year Results From Phase 3 VISTA Trial of EYLEA (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision 178
Feb 10, 2014: pSivida Announces ILUVIEN for DME Accepted by National Health Service Scotland 179
Jan 13, 2014: pSivida Corp. Reports First Orders for ILUVIEN Shipped for U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance 180
Dec 18, 2013: Regeneron Announces FDA Acceptance of EYLEA (aflibercept) Injection Supplemental Biologics License Application for Review for Diabetic Macular Edema Indication 180
Appendix 182
Methodology 182
Coverage 182
Secondary Research 182
Primary Research 182
Expert Panel Validation 182
Contact Us 183
Disclaimer 183